若生智能
Drug Database
ME

meningococcus B & C vaccine

✓ Approved

Abivax · 疫苗 · 疫苗

什么是 meningococcus B & C vaccine？

meningococcus B & C vaccine 是一种疫苗，由Abivax研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司Abivax
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Abivax

治疗适应症

meningococcus B & C vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-08-04

Tea saponin-soybean oil submicron emulsion promotes durable protective immunity against Pasteurella multocida.

Cui Xuemei X, Yu Le L, Zhang Ruiting R, Huang Yee Y et al.

Inactivated Pasteurella multocida (Pm) vaccines are safe and practical for veterinary use, but their protection is often limited by weak cellular immune activation and insufficient durability of antibody responses. This study investigated whether a tea saponin-soybean oil submicron emulsion could improve the durability, breadth and protective efficacy of immune responses induced by an inactivated P. multocida vaccine. Inactivated P. multocida antigen was formulated with tea saponin and soybean oil to generate TS-Pm. The formulation was characterized by particle size, polydispersity, surface charge, morphology and storage stability. Macrophage antigen uptake, cytokine secretion and activation-associated surface markers were examined in vitro. In mice, we evaluated antibody persistence, B-cell differentiation, splenic cellular immunity, pulmonary CD11b+ myeloid phenotypes, systemic tolerability, protection after lethal challenge and draining lymph-node proteomic profiles. TS-Pm formed a stable oil-in-water submicron emulsion of approximately 300 nm with low polydispersity, negative surface charge and preserved morphology after 6 months at 4 °C. In RAW264.7 macrophages, TS-Pm increased antigen uptake, pro-inflammatory cytokine production and CD80, CD86 and MHC-II expression. Compared with alum-adjuvanted vaccine, TS-Pm maintained higher Pm-specific IgG responses, increased both IgG1 and IgG2a, and promoted plasmablast, plasma cell and germinal-center-associated B-cell responses. TS-Pm also enhanced antigen-responsive splenic proliferation, cytokine-producing CD4+ and CD8+ T-cell subsets, and activation-associated phenotypes in pulmonary CD11b+ myeloid cells. After lethal challenge, TS-Pm improved survival to 90%, compared with 60% for Alum-Pm, and reduced pulmonary bacterial burden and lung pathology without evidence of aggravated systemic injury. Draining lymph-node proteomics showed changes associated with antigen processing and presentation, NF-κB-related signaling and immune-cell trafficking. Tea saponin-soybean oil submicron emulsion improved the durability, breadth and protective efficacy of immune responses induced by an inactivated P. multocida vaccine. These findings identify TS-Pm as a practical plant-derived adjuvant formulation for inactivated bacterial vaccines requiring sustained humoral and cellular immunity.

PMID 42548716
阅读全文 →
PubMedCell reports. Medicine2026-08-04

Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses.

Chen Hongyu H, Yuan Longhai L, Yang Hao H, Huang Qing Q et al.

Two mRNA vaccines (V1 and V2) from our previous study, encoding different CHIKV structural proteins, exhibit distinct immune effects and protective efficacy. However, the immune mechanisms underlying these differences remain unclear. In this study, we use an integrated multi-omics approach (single-cell RNA sequencing, immune repertoire sequencing, and Olink cytokine profiling) to elucidate the differential immune cell activation states induced by the two vaccines and the potential structural basis of the antigens that may account for these differences. We find that V2 induces sustained B cell activation, predominantly IgG-type memory antibodies, and a robust recall response following viral challenge. By contrast, V1 elicits only transient B cell activation and relatively weak T cell responses. These findings delineate a mechanistic pathway linking mRNA antigen structure to immune activation, functional differentiation, immunological memory, and protective efficacy. This work enhances our understanding of the immunological mechanisms underlying CHIKV mRNA vaccination and offers insights for rational vaccine antigen design.

PMID 42546698
阅读全文 →
PubMedHepatology international2026-08-04

National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment.

Charatcharoenwitthaya Phunchai P, Tanwandee Tawesak T, Tangkijvanich Pisit P, Piratvisuth Teerha T et al.

Despite sustained universal infant hepatitis B vaccination, chronic hepatitis B (CHB) remains an important cause of cirrhosis and hepatocellular carcinoma in Thailand, particularly among adults born before vaccine implementation. This article summarizes the 2026 National Guideline on Elimination of Viral Hepatitis B in Thailand and presents a health-system framework for addressing the remaining disease burden. The guideline was developed by a multidisciplinary expert panel using evidence from international recommendations, peer-reviewed literature, national epidemiological data, implementation studies, and health economic analyses. The recommendations were formulated using the GRADE framework and adapted for implementation within Thailand's Universal Health Coverage system. The national strategy prioritizes birth-cohort HBsAg screening for adults born before 1992, simplified evidence-based treatment eligibility incorporating non-invasive fibrosis assessment and virological criteria, and first-line use of high genetic-barrier nucleos(t)ide analogs. Prevention of mother-to-child transmission prioritizes HBV DNA-guided antiviral prophylaxis, with simplified implementation pathways reserved for settings with substantial diagnostic constraints. Long-term care emphasizes structured monitoring, appropriate specialist referral, conservative treatment discontinuation criteria, defined retreatment thresholds, and risk-based semiannual ultrasound surveillance for hepatocellular carcinoma. Integration with antenatal services, HIV programs, and primary care facilities supports decentralized delivery and continuity of care. Thailand's 2026 hepatitis B guideline operationalizes evidence-based CHB management within a publicly financed decentralized health system and provides a scalable model for expanding hepatitis B diagnosis and treatment in endemic settings.

PMID 42547747
阅读全文 →
PubMedSurgery2026-08-04

Robot-assisted surgery combined with enhanced recovery after surgery in the treatment of hiatal hernia in children.

Zhu Daiwei D, Zheng Zebing Z, Tang Chengyan C, Xia Xingrong X et al.

To explore the efficacy of combining robot-assisted surgery with perioperative measures of enhanced recovery after surgery in children with hiatal hernia. Seventy-two children with hiatal hernia who underwent surgical treatment in our department between January 2014 and December 2024 were retrospectively enrolled. The patients were divided into 3 groups according to the period of admission. Group A (n = 29) received conventional laparoscopic surgery and conventional perioperative management; group B (n = 27) received conventional laparoscopic surgery and the enhanced recovery after surgery protocol; and group C (n = 16) received robotic-assisted surgery and the enhanced recovery after surgery protocol. The collected data included age at surgery, weight at surgery, operation time, intraoperative blood loss, postoperative inflammatory markers, time to first postoperative bowel movement, postoperative pain assessment, postoperative hospital stay, postoperative complications, and hospitalization costs. No significant differences were observed in age at surgery, weight at surgery, and operative time (P > .05). Group C was associated with a significantly reduced intraoperative blood loss compared with groups A and B (P < .05). Groups B and C were associated with a significantly shorter postoperative hospital stay and an earlier time to first postoperative bowel movement compared with group A (P < .05). No statistically significant difference was observed in the complication rates among the 3 groups (P > .05). The hospitalization cost in group C was significantly higher than that in groups A and B (P < .05). As for inflammatory markers, the C-reactive protein level on postoperative day 1 was significantly lower in groups B and C compared with group A (P < .05), whereas the white blood cell levels did not differ significantly among the 3 groups (P > .05). Comparisons of postoperative pain scores among the 3 groups revealed that groups B and C had significantly lower scores at both 6 and 24 hours postoperatively compared with group A (P < .05). Robot-assisted surgery in the treatment of hiatal hernia in children demonstrates safety and efficacy, offering distinct advantages in meticulous anatomic exposure and accurate suturing. In combination with the enhanced recovery after surgery protocol, it reduces surgical trauma, alleviates postoperative pain, and promotes early recovery. This combined approach is recommended for clinical application.

PMID 42547317
阅读全文 →
PubMedThe Lancet. Infectious diseases2026-08-04

Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.

Hisamoto Koji K, Yamanaka Masaki M, Nomura Masayasu M, Kanno Nobufumi N et al.

Efficacy of the nine-valent human papillomavirus (9vHPV; HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine was shown in females and inferred for males through immunobridging. We evaluated the efficacy of the 9vHPV vaccine in males aged 16-26 years. This randomised, double-blind, placebo-controlled, efficacy, immunogenicity, and safety phase 3 trial was conducted at 22 clinical research, hospital, medical, or treatment sites in Japan, with masking of investigators, sponsor personnel, and participants. Healthy males aged 16-26 years with no history of human papillomavirus (HPV)-related lesions and no previous HPV vaccination were randomly assigned (1:1) centrally, using permutated blocks (block sizes of four), to receive three intramuscular injections of the 9vHPV vaccine or placebo (saline) at day 1, month 2, and month 6. The primary and secondary efficacy endpoints were the combined incidences of 6-month anogenital persistent infection related to HPV6, 11, 16, and 18 and HPV31, 33, 45, 52, and 58. Anogenital swabs and external genital tissue samples were tested for the presence of HPV DNA. Tissue samples were adjudicated for histopathology diagnosis. The primary and secondary efficacy evaluations were tested for superiority with a margin of 0% in the per-protocol population. Another secondary endpoint was antibody responses to each vaccine-targeted HPV type at month 7; immunogenicity analyses were conducted in the per-protocol immunogenicity population. Safety was assessed in participants who received at least one dose of vaccine or placebo. This study is registered with ClinicalTrials.gov (NCT04635423) and is completed. Between Nov 30, 2020, and Dec 25, 2021, 1059 participants were enrolled and randomly assigned to receive the 9vHPV vaccine (n=529) or placebo (n=530). Vaccine efficacy for the primary and secondary endpoints was 89·3% (95% CI 55·4-98·2; p=0·0002) and 63·5% (2·7-86·0; p=0·023), respectively, in the initial efficacy analysis based on a visit cutoff date of Dec 29, 2023, and 91·6% (67·7-98·6) and 72·9% (38·7-89·3) in the end-of-study efficacy analysis based on a visit cutoff date of July 16, 2024. Seroconversion rates were greater than 98% for each vaccine-targeted HPV type. Injection-site adverse events were reported in 370 (70%) of 529 9vHPV vaccine recipients and 162 (31%) of 530 placebo recipients, and vaccine-related systemic adverse events in 58 (11%) vaccine recipients and 52 (10%) placebo recipients; most cases were mild or moderate. No deaths, vaccine-related serious adverse events, or discontinuations due to adverse events were reported. The 9vHPV vaccine prevents anogenital persistent infection related to vaccine-targeted HPV types in males and has an acceptable safety profile. These findings support the use of the 9vHPV vaccine in males to prevent HPV-related anogenital diseases. Merck Sharp & Dohme. For the Japanese translation of the abstract see Supplementary Material section.

PMID 42546724
阅读全文 →
PubMedBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026-08-04

Distribution of hepatitis B virus genotypes and demography in the general population of Karachi, Sindh.

Farooq Saba S, Iqbal Hana'a H, Faiz Sirmast S, Ahsan Farwa F et al.

Hepatitis B is a major global burden, with 253 million infected people. There are at least ten Hepatitis B virus (HBV) genotypes and 35 subgenotypes, with distinct ethno-geographical distributions and manifest differences in their biological characteristics, display close association with clinical outcomes, severity of disease, and response to antiviral therapy. The aim of the study was to identify the predominant circulating genotypes of HBV in the population of Karachi, Sindh. A demographic assessment was conducted alongside a serological evaluation of markers specifically HBsAg, HBsAb, HBeAb, and HBcAb to determine the clinical infection profile of the study cohort. An initial molecular identification was performed by first round of PCR via specific primers P1 and S1-2 for PreS1/S2 gene. The HBV genotypes (A to F) was determined by nested PCR using primer pairs for the conserved sequence of HBV pre-S gene and S gene, and subsequently validated by phylogenetic analysis. The study findings indicated that the mean age of the study participants was 33.94 years, with a median age of 31.5 years. The percentage of HBV positive female and male were 51.5% and 48.5%, respectively. The results of this pilot study indicated that the probable predominant genotype circulating in Karachi is D, followed by B and C. Mixed infection of B, C, and D was also observed. Almost all the D positive samples were positive for HBsAg.

PMID 42547661
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcus B & C vaccine